Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL

Página do item simplificado
dc.contributor.authorFafa, Barbara P.
dc.contributor.authorLouzada-Junior, Paulo
dc.contributor.authorTitton, David C.
dc.contributor.authorZandonade, Eliana
dc.contributor.authorRanza, Roberto
dc.contributor.authorLaurindo, Ieda
dc.contributor.authorPecanha, Paula
dc.contributor.authorRanzolin, Aline
dc.contributor.authorHayata, Andre L.
dc.contributor.authorDuarte, Angela
dc.contributor.authorSilveira, Ines G.
dc.contributor.authorCosta, Izaias
dc.contributor.authorMacieira, Jose C.
dc.contributor.authorGuedes-Barbosa, Luiz S.
dc.contributor.authorBertolo, Manoel B.
dc.contributor.authorSauma, Maria Fatima Lobato da C.
dc.contributor.authorSilva, Marilia B. G.
dc.contributor.authorFreire, Marlene
dc.contributor.authorScheinberg, Morton A.
dc.contributor.authorFernandes, Vander
dc.contributor.authorBianchi, Washington
dc.contributor.authorMiranda, Jose R. S.
dc.contributor.authorPinheiro, Geraldo R. C.
dc.contributor.authorCarvalho, Hellen M. S.
dc.contributor.authorBrenol, Claiton Viegas
dc.contributor.authorPereira, Ivanio A.
dc.contributor.authorWerner de Castro, Glaucio Ricardo
dc.contributor.authorBertacini de Morais, Julio C.
dc.contributor.authorOliveira, Sheila K. F.
dc.contributor.authorAbreu, Mirhelen Mendes de [UNIFESP]
dc.contributor.authorToledo, Roberto A.
dc.contributor.authorPinheiro, Marcelo M. [UNIFESP]
dc.contributor.authorVieira, Walber Pinto
dc.contributor.authorValim, Valeria
dc.contributor.authorBIOBADABRASIL
dc.contributor.institutionUniv Fed Espirito Santo
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionUniv Fed Parana
dc.contributor.institutionUniversidade Federal de Uberlândia (UFU)
dc.contributor.institutionUniversidade Federal de Pernambuco (UFPE)
dc.contributor.institutionClin Reumatol Osasco
dc.contributor.institutionPontificia Univ Catolica Rio Grande Sul PUC
dc.contributor.institutionUniversidade Federal de Mato Grosso do Sul (UFMS)
dc.contributor.institutionUniv Fed Sergipe
dc.contributor.institutionUniv Fed Mato Grosso
dc.contributor.institutionUniversidade Estadual de Campinas (UNICAMP)
dc.contributor.institutionFed Univ Para
dc.contributor.institutionHosp Univ Evangel Curitiba
dc.contributor.institutionUniv Fed Triangulo Mineiro
dc.contributor.institutionCtr Hosp Abreu Sodre AACD
dc.contributor.institutionUniv Cuiaba
dc.contributor.institutionSanta Casa Misericordia Rio de Janeiro
dc.contributor.institutionUniv Estacio Sa
dc.contributor.institutionArtroctr Clin Med
dc.contributor.institutionUniversidade do Estado do Rio de Janeiro (UERJ)
dc.contributor.institutionHosp Base Dist Fed
dc.contributor.institutionUniv Fed Rio Grande do Sul
dc.contributor.institutionHosp Clin Porto Alegre
dc.contributor.institutionUniversidade Federal de Santa Catarina (UFSC)
dc.contributor.institutionUniv Sul Santa Catarina
dc.contributor.institutionUniversidade Federal do Rio de Janeiro (UFRJ)
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionHosp Geral Fortaleza
dc.date.accessioned2016-01-24T14:40:25Z
dc.date.available2016-01-24T14:40:25Z
dc.date.issued2015-05-01
dc.description.abstractTreatment survival with biological therapy may be influenced by many factors, and it seems to be different among various rheumatic diseases and biological agents. the goal of the study was to compare the drug survival and the causes of discontinuation of anti-tumoral necrosis factor (anti-TNF) therapy in ankylosing spondylitis (AS) with rheumatoid arthritis (RA). Study participants were a cohort from the Brazilian Registry of Biological Therapies in Rheumatic Diseases (BIOBADABRASIL) between 2008 and 2012. the observation time was up to 4 years following the introduction of the first treatment. Gender, age, disease duration, disease activity, comorbidities, and concomitant therapies were assessed. A total of 1303 patients were included: 372 had AS and 931 had RA in which 38.7%(n=504) used infliximab (IFX), 34.9 % (n=455) used adalimumab (ADA), and 26.4 % (n=344) used etanercept (ETA). the anti-TNF drug survival of patients with AS was 63.08 months (confidence interval (CI) 60.24, 65.92) and patients with RA was 47.5 months (CI 45.65, 49.36). It was significant higher in AS (log-rank; p=0.001). Patients with RA discontinued anti-TNF more than patients with AS when adjusted to gender and corticosteroid. the adjHR (95 % CI) was 1.6 (1.14, 2.31). Female patients who were also corticosteroid users, but not of advanced age, have shown lower survival for both diseases (log-rank, p=0.001). the discontinuation rate of IFX, but not of ADA or ETA, was significantly higher in RA than in SA; HR (95 % CI) was 2.49 (1.46, 4.24). the main causes of discontinuation were ineffectiveness and adverse event in both diseases. AS patients have better drug survival adjusted to gender, age, and corticosteroid. This results appear to be related to the disease mechanism.en
dc.description.affiliationUniv Fed Espirito Santo, Univ Hosp Cassiano Antonio de Moraes, Dept Clin Med, Rheumatol Div,Med Dept, BR-29040090 Vitoria, ES, Brazil
dc.description.affiliationUniv São Paulo, Fac Med, Med, Reumatol, BR-14049 Ribeirao Preto, SP, Brazil
dc.description.affiliationUniv Fed Parana, BR-80060000 Curitiba, Parana, Brazil
dc.description.affiliationUniv Fed Espirito Santo, Posgrad Saude Coletiva, BR-29040090 Vitoria, ES, Brazil
dc.description.affiliationUniv Fed Uberlandia, BR-38400 Uberlandia, MG, Brazil
dc.description.affiliationUniv São Paulo, Fac Med, Hosp Clin, BR-09500900 São Paulo, SP, Brazil
dc.description.affiliationUniv Fed Pernambuco, Hosp Clin, Recife, PE, Brazil
dc.description.affiliationClin Reumatol Osasco, São Paulo, Brazil
dc.description.affiliationPontificia Univ Catolica Rio Grande Sul PUC, Porto Alegre, RS, Brazil
dc.description.affiliationUniv Fed Mato Grosso do Sul, Campo Grande, MS, Brazil
dc.description.affiliationUniv Fed Sergipe, Aracaju, Sergipe, Brazil
dc.description.affiliationUniv Fed Mato Grosso, Cuiaba, Mato Grosso, Brazil
dc.description.affiliationUniv Estadual Campinas, Campinas, SP, Brazil
dc.description.affiliationFed Univ Para, BR-66059 Belem, Para, Brazil
dc.description.affiliationHosp Univ Evangel Curitiba, Curitiba, Parana, Brazil
dc.description.affiliationUniv Fed Triangulo Mineiro, Uberaba, MG, Brazil
dc.description.affiliationCtr Hosp Abreu Sodre AACD, São Paulo, SP, Brazil
dc.description.affiliationUniv Cuiaba, Hosp Geral Univ, Cuiaba, Mato Grosso, Brazil
dc.description.affiliationSanta Casa Misericordia Rio de Janeiro, Rio de Janeiro, Brazil
dc.description.affiliationUniv Estacio Sa, Rio de Janeiro, RJ, Brazil
dc.description.affiliationArtroctr Clin Med, São Paulo, Brazil
dc.description.affiliationUniv Estado Rio de Janeiro, Reumatol, Rio de Janeiro, RJ, Brazil
dc.description.affiliationHosp Base Dist Fed, Brasilia, DF, Brazil
dc.description.affiliationUniv Fed Rio Grande do Sul, Dept Internal Med, Porto Alegre, RS, Brazil
dc.description.affiliationHosp Clin Porto Alegre, Div Rheumatol, Porto Alegre, RS, Brazil
dc.description.affiliationUniv Santa Catarina, Div Reumatol, Florianopolis, SC, Brazil
dc.description.affiliationUniv Sul Santa Catarina, Hosp Governador Ramos, Rheumatol, Florianopolis, SC, Brazil
dc.description.affiliationUniv São Paulo, Reumatol CEDMAC, São Paulo, SP, Brazil
dc.description.affiliationUniv Fed Rio de Janeiro, Inst Pediat Martagao Gesteira, Rio de Janeiro, Brazil
dc.description.affiliationUniv Fed Rio de Janeiro, Reumatol, Rio de Janeiro, RJ, Brazil
dc.description.affiliationFac Med Sao Jose do Rio Preto, Sao Jose Do Rio Preto, SP, Brazil
dc.description.affiliationUniversidade Federal de São Paulo, Reumatol, São Paulo, SP, Brazil
dc.description.affiliationHosp Geral Fortaleza, Fortaleza, Ceara, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Reumatol, São Paulo, SP, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipBrazilian Society of Rheumatology
dc.format.extent921-927
dc.identifierhttp://dx.doi.org/10.1007/s10067-015-2929-7
dc.identifier.citationClinical Rheumatology. London: Springer London Ltd, v. 34, n. 5, p. 921-927, 2015.
dc.identifier.doi10.1007/s10067-015-2929-7
dc.identifier.issn0770-3198
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/39028
dc.identifier.wosWOS:000353353400015
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofClinical Rheumatology
dc.rightsAcesso restrito
dc.rights.licensehttp://www.springer.com/open+access/authors+rights?SGWID=0-176704-12-683201-0
dc.subjectAnkylosing spondylitisen
dc.subjectAnti-TNFen
dc.subjectBiological therapyen
dc.subjectRheumatoid arthritisen
dc.subjectSurvivalen
dc.titleDrug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASILen
dc.typeArtigo
Arquivos
Coleções
Em verificação - Geral